Suppressing glycolysis by selective inhibition of PFKFB3 isozyme is considered to be a promising therapeutic target due to its strong allosteric activity towards PFK1, which stimulates glycolysis and often overexpressed in most of the cancers. Here, PFKM is linked to cancer.